FORMULATION AND EVALUATION OF NASAL IN- SITU GEL FOR THE TREATMENT OF MIGRAINE

The aim of the present study is to overcome the limitations of nasal cavity like low residence time by using in situ gel forming nasal drug delivery system prepared from polymers that exhibit phase transition (Sol-Gel) and pseudo plastic behaviour to minimize interference within the mucociliary clearance. It the increasing of the delivery residence of the delivery system and enhancing bioavailability. Rizatriptan benzoate is a selective serotonin (5-hydroxytryptamine; 5-HT) type 1B and 1D receptor agonist ("triptan") commonly used for the treatment of a migraine and completely absorbed from GIT, but absolute bioavailability (as conventional tablet) is 45%, indicating the first-pass metabolism, which is due to the metabolism of the drug by monoamine oxidase A isoenzyme (MAO-A) to an inactive indole acetic acid metabolite with the advent of new era of pharmaceutical dosage forms, nasal drug delivery system has established itself as an integral part of novel drug delivery system. Nasal gel is prepared by using gelling agent such as Chitosan HCL, HPMC K4M, Carbopol 934, Sodium alginate, Gellun gum and Sod. β-Glycerophosphate and other excipients. Optimized Batch PF9 was observed to be the best batch.

Keywords: Rizatriptan benzoate, Chitosan HCL, Sod. β-Glycerophosphate , Sodium alginate.